Ascendis Pharma A/S reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 266.72 million compared to EUR 51.17 million a year ago. Net loss was EUR 481.45 million compared to EUR 583.19 million a year ago.

Basic loss per share from continuing operations was EUR 8.55 compared to EUR 10.4 a year ago. Diluted loss per share from continuing operations was EUR 8.55 compared to EUR 10.4 a year ago.